He stays current.

He stays current.

So does his advanced
prostate cancer therapy.

Graph showing downward trend of testosterone levels.
Testosterone Suppression

ELIGARD’s innovative ATRIGEL® Delivery System provides controlled  drug release enabling consistent suppression of testicular testosterone synthesis throughout the dosing period1

Calendar Icon
Flexible Dosing

ELIGARD offers four (4) dosing options to meet different patient needs2

Flexible Dosing
Needle Icon
Enhanced Patient Experience

ELIGARD’s subcutaneous injection allows for numerous injection sites contributing to the patient’s comfort level.3

Enhanced Patient Experience
Scanner Icon
Inventory and Patient Management
Solutions for Your Practice

Stay focused on patients, not paperwork, with TOLMARsync®.

Piggy Bank

Our experts will verify insurance benefits and assist with prior authorizations, appeals, billing and coding inquiries

Patient Assistance

Patients who meet eligibility criteria may receive ELIGARD via our Patient Assistance Program.

Phone Icon

Order ELIGARD by phone or online.

Tap for safety information


ELIGARD® is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH analogs. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH analogs in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.


ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

Please see full Prescribing Information for ELIGARD.


  1. Sartor O. Eur Urol. 2006
  2. ELIGARD® (leuprolide acetate) for injectable suspension 7.5 mg, 22.5 mg, 30 mg, 45 mg prescribing information. Fort Collins, CO: Tolmar Therapeutics, Inc.; 2019.
  3. Prettyman J. Urologic Nursing 2019
  4. Shore N, et al., BJU Int. 2016